Literature DB >> 8574166

Fatal bone marrow necrosis following fludarabine administration in a patient with indolent lymphoma.

D M Aboulafia1, T Demirer.   

Abstract

We report the first known case of fulminant bone marrow necrosis (BMN) occurring after infusion of fludarabine monophosphate in a patient with recurrent low-grade non-Hodgkin's lymphoma (NHL). Extensive BMN is characterized by the development of fever, bony pain, a leukoerythroblastic peripheral blood film, variable degrees of pancytopenia and elevations in lactate dehydrogenase and alkaline phosphatase. The diagnosis of BMN is rarely entertained ante-mortem. Although the precise role chemotherapy may have played in triggering fatal BMN remains speculative, we alert clinicians to be aware of this entity as more patients with indolent lymphomas and leukemias are treated with this and other potent nucleoside analogs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8574166     DOI: 10.3109/10428199509059674

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

1.  Extensive bone marrow necrosis resolved by allogeneic umbilical cord blood mesenchymal stem cell transplantation in a chronic myeloid leukemia patient.

Authors:  Y Pan; X Wang; C Wang; Q Zhang; R Xi; J Bai; H Bai
Journal:  Bone Marrow Transplant       Date:  2015-05-11       Impact factor: 5.483

Review 2.  Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

Authors:  J C Adkins; D H Peters; A Markham
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

3.  Precursor T-cell acute lymphoblastic leukemia presenting with bone marrow necrosis: a case report.

Authors:  Najmaddin S H Khoshnaw; Hisham A Al-Rawi; Beston F Nore
Journal:  J Med Case Rep       Date:  2012-10-11

4.  Bone marrow necrosis secondary to metastatic adenocarcinoma revealed by 18F-FDG PET/CT: A clinical case report.

Authors:  Ping Dong; Rong Tian; Lin Li; Minggang Su
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.